Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma.

PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.


Options:
A: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II
C: Arm Label: doxorubicin + vinblastine + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: doxorubicin hydrochloride, Drug: gemcitabine hydrochloride, Drug: vinblastine, Procedure: fludeoxyglucose F 18 positron-emission tomography (PET) scan, Procedure: CT scan | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: fludeoxyglucose F 18 positron-emission tomography (PET) scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: CT scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine
D: Arm Label: Group 1 (favorable prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 2 (intermediate prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 3 (poor prognosis); Type: EXPERIMENTAL; Interventions: Drug: carmustine, Drug: cisplatin, Drug: cytarabine, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: gemcitabine hydrochloride, Drug: ifosfamide, Drug: melphalan, Drug: methylprednisolone, Drug: mitoguazone, Drug: vindesine, Drug: vinorelbine tartrate, Procedure: allogeneic hematopoietic stem cell transplantation, Procedure: autologous hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: mitoguazone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: allogeneic hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis)

Answer: D